Footer (site)
CancerNetwork | ConsultantLive | Diagnostic Imaging | Psychiatric Times | Search Medica | Physicians Practice
© 1996 - 2010 UBM Medica LLC, a Privacy Statement - Terms of Service - Advertising Information
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
